Loading…
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA...
Saved in:
Published in: | British Journal of Cancer 1999-04, Vol.80 (1-2), p.286-294 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993 |
---|---|
cites | cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993 |
container_end_page | 294 |
container_issue | 1-2 |
container_start_page | 286 |
container_title | British Journal of Cancer |
container_volume | 80 |
creator | Witte, J H de Sweep, C G J Klijn, J G M Grebenschikov, N Peters, H A Look, M P Tienoven, ThH van Heuvel, J J T M Vries, J Bolt-De Benraad, ThJ Foekens, J A |
description | The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000
g
pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient
r
s
= 0.75,
P
< 0.001 for tPA and
r
= 0.50,
P
< 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients. |
doi_str_mv | 10.1038/sj.bjc.6690353 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69859634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</originalsourceid><addsrcrecordid>eNp1kc9v0zAcxS0EYqVw5QbyASF2SGfHdhJfJlUTPyZNogc4W477TesosYvtFHbhb8cjZYwDJ8t-n_e-X_kh9JKSFSWsuYj9qu3NqqokYYI9QgvK66oQrKGP0YIQUhdEluQMPYuxJySLtXiKzrJV5htZoJ-b4HfOx2QNPuphAuw7nGyMExTp9gD4MOg4Wud34LA2yR518gG_S5v1OdZui22K2PjxMMAP_N2mPU57wHfOgmLr9ra1v_nN-rqg5_kFtwF0TNhoZyA8R086PUR4cTqX6OuH91-uPhU3nz9eX61vCpM3TgUH0XQdoaJpa86okJzQLUgt2q7qWl42UAKjrdDAJeMNLTlUjEshNbTQSMmW6HLOPUztCFsDLgU9qEOwow63ymur_lWc3audP6qSVaWUVQ54ewoI_tsEManRRgPDoB34KapKNiJjPIOrGTTBxxigux9CibqrTMVe5crUqbJseP1wtQf43FEG3pwAHY0eupB_zsa_XN00dQ5aoosZi1lxOwiq91Nw-Vf_P_nV7HA6TQHuE__ovwC7pbpJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69859634</pqid></control><display><type>article</type><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><source>Wiley</source><source>PubMed Central</source><creator>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</creator><creatorcontrib>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</creatorcontrib><description>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000
g
pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient
r
s
= 0.75,
P
< 0.001 for tPA and
r
= 0.50,
P
< 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1476-5381</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690353</identifier><identifier>PMID: 10390010</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer Research ; Cytosol - metabolism ; Drug Resistance ; Enzyme-Linked Immunosorbent Assay ; Epidemiology ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Molecular Medicine ; Multivariate Analysis ; Oncology ; Plasminogen Activator Inhibitor 1 - metabolism ; Prognosis ; Proportional Hazards Models ; Regular ; regular-article ; Survival Analysis ; Tissue Plasminogen Activator - metabolism ; Tumors</subject><ispartof>British Journal of Cancer, 1999-04, Vol.80 (1-2), p.286-294</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</citedby><cites>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362996/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362996/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1788735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10390010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Witte, J H de</creatorcontrib><creatorcontrib>Sweep, C G J</creatorcontrib><creatorcontrib>Klijn, J G M</creatorcontrib><creatorcontrib>Grebenschikov, N</creatorcontrib><creatorcontrib>Peters, H A</creatorcontrib><creatorcontrib>Look, M P</creatorcontrib><creatorcontrib>Tienoven, ThH van</creatorcontrib><creatorcontrib>Heuvel, J J T M</creatorcontrib><creatorcontrib>Vries, J Bolt-De</creatorcontrib><creatorcontrib>Benraad, ThJ</creatorcontrib><creatorcontrib>Foekens, J A</creatorcontrib><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><title>British Journal of Cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000
g
pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient
r
s
= 0.75,
P
< 0.001 for tPA and
r
= 0.50,
P
< 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Cytosol - metabolism</subject><subject>Drug Resistance</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Regular</subject><subject>regular-article</subject><subject>Survival Analysis</subject><subject>Tissue Plasminogen Activator - metabolism</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1476-5381</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNp1kc9v0zAcxS0EYqVw5QbyASF2SGfHdhJfJlUTPyZNogc4W477TesosYvtFHbhb8cjZYwDJ8t-n_e-X_kh9JKSFSWsuYj9qu3NqqokYYI9QgvK66oQrKGP0YIQUhdEluQMPYuxJySLtXiKzrJV5htZoJ-b4HfOx2QNPuphAuw7nGyMExTp9gD4MOg4Wud34LA2yR518gG_S5v1OdZui22K2PjxMMAP_N2mPU57wHfOgmLr9ra1v_nN-rqg5_kFtwF0TNhoZyA8R086PUR4cTqX6OuH91-uPhU3nz9eX61vCpM3TgUH0XQdoaJpa86okJzQLUgt2q7qWl42UAKjrdDAJeMNLTlUjEshNbTQSMmW6HLOPUztCFsDLgU9qEOwow63ymur_lWc3audP6qSVaWUVQ54ewoI_tsEManRRgPDoB34KapKNiJjPIOrGTTBxxigux9CibqrTMVe5crUqbJseP1wtQf43FEG3pwAHY0eupB_zsa_XN00dQ5aoosZi1lxOwiq91Nw-Vf_P_nV7HA6TQHuE__ovwC7pbpJ</recordid><startdate>19990401</startdate><enddate>19990401</enddate><creator>Witte, J H de</creator><creator>Sweep, C G J</creator><creator>Klijn, J G M</creator><creator>Grebenschikov, N</creator><creator>Peters, H A</creator><creator>Look, M P</creator><creator>Tienoven, ThH van</creator><creator>Heuvel, J J T M</creator><creator>Vries, J Bolt-De</creator><creator>Benraad, ThJ</creator><creator>Foekens, J A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990401</creationdate><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><author>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Cytosol - metabolism</topic><topic>Drug Resistance</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Regular</topic><topic>regular-article</topic><topic>Survival Analysis</topic><topic>Tissue Plasminogen Activator - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Witte, J H de</creatorcontrib><creatorcontrib>Sweep, C G J</creatorcontrib><creatorcontrib>Klijn, J G M</creatorcontrib><creatorcontrib>Grebenschikov, N</creatorcontrib><creatorcontrib>Peters, H A</creatorcontrib><creatorcontrib>Look, M P</creatorcontrib><creatorcontrib>Tienoven, ThH van</creatorcontrib><creatorcontrib>Heuvel, J J T M</creatorcontrib><creatorcontrib>Vries, J Bolt-De</creatorcontrib><creatorcontrib>Benraad, ThJ</creatorcontrib><creatorcontrib>Foekens, J A</creatorcontrib><collection>SpringerOpen</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Witte, J H de</au><au>Sweep, C G J</au><au>Klijn, J G M</au><au>Grebenschikov, N</au><au>Peters, H A</au><au>Look, M P</au><au>Tienoven, ThH van</au><au>Heuvel, J J T M</au><au>Vries, J Bolt-De</au><au>Benraad, ThJ</au><au>Foekens, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</atitle><jtitle>British Journal of Cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-04-01</date><risdate>1999</risdate><volume>80</volume><issue>1-2</issue><spage>286</spage><epage>294</epage><pages>286-294</pages><issn>0007-0920</issn><eissn>1476-5381</eissn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000
g
pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient
r
s
= 0.75,
P
< 0.001 for tPA and
r
= 0.50,
P
< 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10390010</pmid><doi>10.1038/sj.bjc.6690353</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British Journal of Cancer, 1999-04, Vol.80 (1-2), p.286-294 |
issn | 0007-0920 1476-5381 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362996 |
source | Wiley; PubMed Central |
subjects | Adult Aged Aged, 80 and over Biological and medical sciences Biomedical and Life Sciences Biomedicine Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Research Cytosol - metabolism Drug Resistance Enzyme-Linked Immunosorbent Assay Epidemiology Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Molecular Medicine Multivariate Analysis Oncology Plasminogen Activator Inhibitor 1 - metabolism Prognosis Proportional Hazards Models Regular regular-article Survival Analysis Tissue Plasminogen Activator - metabolism Tumors |
title | Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20tissue-type%20plasminogen%20activator%20(tPA)%20and%20its%20complex%20with%20the%20type-1%20inhibitor%20(PAI-1)%20in%20breast%20cancer&rft.jtitle=British%20Journal%20of%20Cancer&rft.au=Witte,%20J%20H%20de&rft.date=1999-04-01&rft.volume=80&rft.issue=1-2&rft.spage=286&rft.epage=294&rft.pages=286-294&rft.issn=0007-0920&rft.eissn=1476-5381&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690353&rft_dat=%3Cproquest_pubme%3E69859634%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69859634&rft_id=info:pmid/10390010&rfr_iscdi=true |